| 引用本文: | 郑薇薇,郑斌,刘茂柏.中枢性性早熟临床实践指南的质量评价[J].中国现代应用药学,2024,41(1):119-125. |
| ZHENG Weiwei,ZHENG Bin,LIU Maobai.Quality Evaluation of Clinical Practice Guidelines for Central Precocious Puberty[J].Chin J Mod Appl Pharm(中国现代应用药学),2024,41(1):119-125. |
|
| 摘要: |
| 目的 了解中枢性性早熟临床实践指南与共识的现状，评价和分析其质量，为中枢性性早熟临床决策和指南共识的修订与完善提供参考。方法 计算机检索PubMed、OVID、中国知网、万方数据库、国际指南联盟、Guidelines International Network(GIN)、National Institute for Health and Care Excellence(NICE)、Scottish Intercollegiate Guidelines Network(SIGN)、American Society of Clinical Oncology(ASCO)、American Urological Association(AUA)等中英文数据库和相关网站；检索时间从建库到2021年5月；由2名研究人员严格按照纳入与排除标准进行文献筛选，纳入临床实践指南。运用指南研究与评价工具(Appraisal of Guidelines for Research & Evaluation II，AGREE II)评价和分析其质量，对药物治疗推荐意见进行比较总结。结果 本研究共纳入指南5篇。AGREE II质量评价结果显示，6个领域的平均标准化得分：范围和目的86.6%、参与人员43.9%、严谨性22.3%、清晰性75.5%、应用性40.0%、独立性40.8%；4篇指南推荐等级为B级，1篇为C级。结论 中枢性性早熟临床实践指南总体方法学质量中等偏低，应严格按照循证指南的制定标准及AGREE II各领域要求，制定高质量中枢性性早熟循证临床实践指南。 |
| 关键词: 中枢性性早熟 指南 AGREE II 质量评价 |
| DOI：10.13748/j.cnki.issn1007-7693.20223176 |
| 分类号:R969.3 |
| 基金项目:福建省卫生健康科研人才培养项目(2019-1-36) |
|
| Quality Evaluation of Clinical Practice Guidelines for Central Precocious Puberty |
|
ZHENG Weiwei, ZHENG Bin, LIU Maobai
|
|
Fujian Medical University Union Hospital, Fuzhou 350001, China
|
| Abstract: |
| OBJECTIVE To understand the status of clinical practice guidelines and consensus on central precocious puberty, evaluate and analyze its quality, and to provide reference for the revision and improvement of clinical decision-making and consensus on central precocious puberty. METHODS PubMed, OVID, CNKI, Wanfang database, International Guideline Alliance, Guidelines International Network(GIN), National Institute for Health and Care Excellence(NICE), Scottish Intercollegiate Guidelines Network(SIGN), American Society of Clinical Oncology(ASCO), American Urological Association(AUA) and other Chinese and English databases and related websites were searched with computer. The retrieval time was from the establishment of the database to May 2021. Two researchers rigorously screened the literature according to inclusion and exclusion criteria, and included clinical practice guidelines. The Appraisal of Guidelines for Research & Evaluation II(AGREE II) was used to evaluate and analyze the quality, and the recommendations for drug therapy were compared and summarized. RESULTS Five guidelines were included in this study. The quality evaluation results of AGREE II showed that the average standardization scores of the six fields were 86.6% for scope and purpose, 43.9% for participants, 22.3% for rigor, 75.5% for clarity, 40.0% for application, and 40.8% for independence. Four guidelines were recommended for grade B and one was recommended for grade C. CONCLUSION The overall methodological quality of clinical practice guidelines for central precocious puberty is moderately to low. High-quality evidence-based clinical practice guidelines for central precocious puberty should be developed strictly in accordance with the formulation standards of evidence-based guidelines and the requirements of each domain of AGREE II. |
| Key words: central precocious puberty guidelines AGREE II quality evaluation |
